Targeting Cancer's Code. Delivering RNA Medicines. Transforming Cancer Cure
Targeted RNA therapeutics that combine tumor-specific antibody delivery with antisense oligonucleotides medicines.
About Carnation Therapeutics Inc
Our History
Carnation Therapeutics Inc. was founded in 2022 with the mission of developing next-generation precision RNA medicines for cancer, with the ultimate goal of improving outcomes for patients facing difficult-to-treat malignancies. We are advancing first-in-class treatments against high-value cancer targets that have remained "undruggable" and beyond the reach of conventional medicines.
Our Technology
We harness the power of antibody–oligonucleotide conjugates (AOCs), an emerging class of targeted therapeutics that deliver antisense oligonucleotides (ASOs) directly to tumor cells. These precision medicines selectively bind messenger RNA (mRNA) and modulate disease‑causing protein expression, offering a targeted approach with the potential for improved efficacy and reduced off‑target toxicity.
Tackling few cancers at a time
Breast Cancer
Breast cancer is one of the most significant global health challenges, affecting more than 2.3 million people worldwide each year. According to the American Cancer Society, it remains the second‑leading cause of cancer death among women in the United States, claiming over 40,000 lives annually. Despite progress in screening and treatment, many patients still face aggressive disease, relapse, or resistance to existing therapies, leaving them with limited options and difficult outcomes. The need for new solutions is urgent. Carnation Therapeutics Inc’s antisense oligonucleotide‑based therapy is designed to directly silence the genetic drivers of breast cancer that current drugs cannot reach, offering a promising new path forward — and renewed hope for patients and their families
Lung Cancer
Lung cancer is a global health crisis, affecting millions of people worldwide. According to the World Health Organization (WHO), lung cancer is the leading cause of cancer deaths, accounting for approximately 1.8 million deaths annually (19.4% of all cancer deaths). The WHO also estimates that 228,840 new cases of lung cancer are diagnosed every year. The stark reality is that lung cancer claims more lives than breast, prostate, and colon cancers combined. Despite advances in cancer research, lung cancer remains a highly aggressive and difficult-to-treat disease, with a five-year survival rate of only around 21%. The need for a cure is urgent, as current treatments often come with harsh side effects and limited success. However, there is hope on the horizon: Carnation Therapeutics Inc's innovative antisense oligonucleotide-based therapy offers promising potential for a lung cancer cure, bringing new hope to patients and their families.
Melanoma
Melanoma is a growing global health concern, affecting over 320,000 people worldwide each year. According to the American Cancer Society, melanoma is the deadliest form of skin cancer, responsible for over 10,000 deaths annually in the United States alone. Despite advances in cancer research, melanoma remains a highly aggressive and difficult-to-treat disease, with a five-year survival rate of only around 20%. The need for a cure is urgent, as current treatments often come with harsh side effects and limited success. However, there is hope on the horizon: Carnation Therapeutics Inc's innovative antisense oligonucleotide-based therapy offers promising potential for a melanoma cure, bringing new hope to patients and their families.
Contact Us
We would love to hear from you.
To learn more about our technology, scientific and business collaborations, write to us.
Carnation Therapeutics Inc
